Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12045056 | 0.89 | KMT2A (0.45) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6790784 | 0.86 | MEN1 (0.47) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6487391 | 0.84 | KDM4E (0.41) | KMT2AMEN1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL6798819 | 0.84 | POLB (0.57) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6489441 | 0.84 | F2 (0.44) | POLBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL27600739 | 0.84 | POLB (0.56) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6795253 | 0.82 | ALDH1A1 (0.39) | POLBNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL6500907 | 0.80 | MMP1 (0.39) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL6501746 | 0.79 | HDAC1 (0.37) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL27678360 | 0.78 | ALDH1A1 (0.44) | POLBNPC1RAB9AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | POLB 1470/4885KMT2A 2457/4885MEN1 2426/4885 |
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | POLB 1209/4885KMT2A 916/4885MEN1 3820/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | POLB 1626/4885KMT2A 573/4885MEN1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.